A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer
Latest Information Update: 25 Aug 2023
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms Neo-PREDICT-HER2
- 16 Sep 2019 Status changed from completed to discontinued.
- 24 Jun 2018 Status changed from discontinued to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology